-
30 Janvier 2026
-
30 Janvier 2026
Ipsen expands pre-clinical pipeline in rare neurodegenerative diseases
PARIS, FRANCE 30 January 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today a new global collaboration and option agreement with Origami Therapeutics for a research stage protein degrader program targeting genetic neurodegenerative diseases. Followin...
-
30 Janvier 2026
-
30 Janvier 2026
Ipsen élargit son portefeuille de produits en phase préclinique dans le domaine des maladies neurodégénératives rares
PARIS, FRANCE 30 janvier 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) annonce aujourd'hui un nouvel accord de collaboration mondiale et d'option avec Origami Therapeutics pour un programme de recherche sur les dégradeurs de protéines ciblant les maladies neu...
-
04 Mars 2026
- 2 mn de lecture
-
04 Mars 2026
- 2 mn de lecture
Moving NET Science Forward Together at ENETS 2026
An article by Dr Marius Tham, Director Global Medical Affairs, Ipsen ...
-
25 Février 2026
- 2 mn de lecture
-
25 Février 2026
- 2 mn de lecture
We’re Ready for ASCO GU 2026: Advancing Knowledge Together
Vanessa Barue, Senior Medical Director, Medical Asset Lead, Global Medical Affairs Oncology...
-
27 Février 2026
- 3 mn de lecture
-
27 Février 2026
- 3 mn de lecture
A model for modern biopharma collaboration — the enduring partnership between Ipsen and IRICoR
In an era where breakthrough science increasingly depends on deep, cross sector collaboration, the longstanding partnership between Ipsen and the teams at the Institute for Research in Immunology and Cancer (IRIC) and its commercialization unit, IRICoR, at...
-
22 Octobre 2025
-
22 Octobre 2025
Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline
PARIS AND MARSEILLE, FRANCE, 22 October 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) and ImCheck Therapeutics today announced they have entered into a definitive share purchase agreement in which Ipsen will acquire all issued and outstanding shares of ImChec...
-
22 Décembre 2025
-
22 Décembre 2025
Ipsen expands early development pipeline with Simcere Zaiming’s innovative antibody drug conjugate
PARIS, FRANCE; 22 DECEMBER 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today an exclusive licensing agreement for global rights outside of Greater China, for SIM0613, an antibody-drug conjugate (ADC) with best-in-class potential. Targeting the LRRC1...
-
22 Mai 2024
- Basel
-
22 Mai 2024
- Basel
-
22 Mai 2024
- Bâle
-
22 Mai 2024
- Bâle